Biomarkers of Habitual Short Sleep and Related Cardiometabolic Risk

习惯性短睡眠和相关心脏代谢风险的生物标志物

基本信息

  • 批准号:
    10734674
  • 负责人:
  • 金额:
    $ 76.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-01 至 2028-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Over one in three Americans regularly sleep less than the recommended 7 hours per night. Alarmingly, adults who maintain habitual short sleep durations (HSSD), such as medical and military personnel, emergency responders, shift workers, and students, are alarmingly ~30% more likely to develop type 2 diabetes (T2D) versus adults who maintain adequate sleep durations. Furthermore, data show that experimentally imposed sleep restriction lasting ~3 days to 2 weeks can impair insulin sensitivity to levels commonly observed in people with pre-diabetes or in aging. However, it is not known if data from rigidly controlled laboratory studies of experimental sleep restriction translates to people with real-world naturalistic HSSD. Furthermore, neither the existing data from epidemiological nor laboratory-controlled studies inform mechanisms or potential health benefits of interventions targeting HSSD. Molecular biomarkers that link risk of T2D with HSSD could help overcome these knowledge gaps by: (1) identifying mechanisms underlying risk of T2D linked to real- world HSSD and (2) informing whether sleep extension reverses such risk. Our preliminary data identified ceramides as important candidate biomarkers that link risk of T2D with short sleep duration. Ceramides are central intermediate lipids in sphingolipid metabolism and are particularly deleterious as they induce insulin resistance and are consistently associated with incidence of cardiometabolic disease including T2D. Thus, our central hypothesis is that ceramides are biomarkers that link risk of T2D with HSSD, and sleep extension is expected to lower plasma ceramides and improve insulin sensitivity. To test our central hypothesis, we will conduct a randomized controlled trial with real-world sleep extension in overweight and obese adults with HSSD. Participants will complete 1 week of baseline monitoring and then be randomized to either sleep extension (target ≥8 hours of nightly time in bed) or HSSD maintenance for 8 weeks at home (intervention segment). Following the baseline and intervention segments participants will complete rigorous overnight laboratory visits to assess plasma ceramides (targeted metabolomics assay) and insulin sensitivity (hyperinsulinemic- euglycemic clamp). Aim 1 will determine the impact of sleep extension on plasma ceramides and Aim 2 will determine the impact of sleep extension on insulin sensitivity. Our expected findings will advance the field by identifying biomarkers that link risk of T2D with HSSD and informing whether sleep extension reverses such risk. This knowledge could improve our ability to quantify, track, and reduce an individual’s risk of T2D over time, which could be especially impactful for people who are less successful with current diet and physical activity-based interventions. If effective, sleep extension would therefore help improve quality of life and reduce the health and economic burdens of T2D on society.
项目摘要/摘要 超过三分之一的美国人睡眠时间经常少于推荐的每晚7小时。令人担忧的是,成年人坚持 习惯性短睡眠持续时间(HSSD),如医疗和军事人员、紧急响应人员、轮班工作人员和 与睡眠充足的成年人相比,学生患2型糖尿病(T2D)的可能性高出约30%,这一点令人震惊 持续时间。此外,数据显示,实验中施加的持续3天至2周的睡眠限制可能会损害 对糖尿病前期或老年人群中常见水平的胰岛素敏感性。然而,目前还不知道数据是否 来自严格控制的实验室研究的实验性睡眠限制转化为现实世界中的自然主义者 HSSD。此外,来自流行病学或实验室对照研究的现有数据都不能为机制提供信息。 或针对HSSD的干预措施的潜在健康益处。T2D与HSSD风险相关的分子生物标志物 可通过以下方式帮助克服这些知识差距:(1)确定与真实的 世界HSSD和(2)通知延长睡眠是否逆转了这种风险。我们的初步数据确定了神经酰胺 作为将T2D风险与短睡眠时间联系起来的重要候选生物标志物。神经酰胺是中枢中间脂类 在鞘脂新陈代谢中,尤其有害,因为它们诱导胰岛素抵抗,并一贯 与包括T2D在内的心脏代谢性疾病的发生率有关。因此,我们的中心假设是神经酰胺是 将T2D风险与HSSD和睡眠时间延长联系起来的生物标记物有望降低血浆神经酰胺并改善 胰岛素敏感性。为了检验我们的中心假设,我们将进行一项随机对照试验,试验对象为真实世界的睡眠 在超重和肥胖的患有HSSD的成年人中推广。参与者将完成为期一周的基线监测,然后 随机选择延长睡眠时间(目标是每晚8小时在床上)或在家中维持8周的≥ (干预部分)。在基线和干预部分之后,参与者将在一夜之间完成严格的 访问实验室以评估血浆神经酰胺(靶向代谢组学分析)和胰岛素敏感性(高胰岛素血症 正血糖钳夹)。目标1将确定睡眠时间延长对血浆神经酰胺的影响,目标2将确定 睡眠时间延长对胰岛素敏感性的影响。我们的预期发现将通过识别生物标记物来推动这一领域的发展 这将T2D的风险与HSSD联系起来,并告知延长睡眠时间是否逆转了这种风险。这一知识可以提高 我们能够量化、跟踪和降低个人随着时间的推移患T2D的风险,这可能对 目前以饮食和体力活动为基础的干预措施不太成功的人。如果有效,延长睡眠时间将 因此,有助于提高生活质量,减轻T2D对社会的健康和经济负担。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher Michael Depner其他文献

Christopher Michael Depner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher Michael Depner', 18)}}的其他基金

Biomarkers and Altered Metabolic Pathways during Sleep Loss and Circadian Disruption
睡眠不足和昼夜节律紊乱期间的生物标志物和代谢途径的改变
  • 批准号:
    10292870
  • 财政年份:
    2021
  • 资助金额:
    $ 76.3万
  • 项目类别:
Biomarkers and Altered Metabolic Pathways during Sleep Loss and Circadian Disruption
睡眠不足和昼夜节律紊乱期间的生物标志物和代谢途径的改变
  • 批准号:
    10475139
  • 财政年份:
    2021
  • 资助金额:
    $ 76.3万
  • 项目类别:
Biomarkers and Altered Metabolic Pathways during Sleep Loss and Circadian Disruption
睡眠不足和昼夜节律紊乱期间的生物标志物和代谢途径的改变
  • 批准号:
    10251958
  • 财政年份:
    2021
  • 资助金额:
    $ 76.3万
  • 项目类别:
Biomarkers and Altered Metabolic Pathways during Sleep Loss and Circadian Disruption
睡眠不足和昼夜节律紊乱期间的生物标志物和代谢途径的改变
  • 批准号:
    10668411
  • 财政年份:
    2021
  • 资助金额:
    $ 76.3万
  • 项目类别:
Biomarkers and Altered Metabolic Pathways during Sleep Loss and Circadian Disruption
睡眠不足和昼夜节律紊乱期间的生物标志物和代谢途径的改变
  • 批准号:
    10018104
  • 财政年份:
    2019
  • 资助金额:
    $ 76.3万
  • 项目类别:
Mechanisms of Insufficient Sleep Contributing to Metabolic Disease Risk and Impact from Weekend Recovery Sleep
睡眠不足导致代谢疾病风险的机制以及周末恢复睡眠的影响
  • 批准号:
    9192556
  • 财政年份:
    2017
  • 资助金额:
    $ 76.3万
  • 项目类别:
Mechanisms of Insufficient Sleep Contributing to Metabolic Disease Risk and Impact from Weekend Recovery Sleep
睡眠不足导致代谢疾病风险的机制以及周末恢复睡眠的影响
  • 批准号:
    9414732
  • 财政年份:
    2017
  • 资助金额:
    $ 76.3万
  • 项目类别:

相似海外基金

Investigating HDAC3 phosphorylation as an epigenetic regulator of memory formation in the adult and aging brain
研究 HDAC3 磷酸化作为成人和衰老大脑记忆形成的表观遗传调节剂
  • 批准号:
    10752404
  • 财政年份:
    2023
  • 资助金额:
    $ 76.3万
  • 项目类别:
The Health of Aging Parents of Adult Children with Serious Conditions
患有严重疾病的成年子女的年迈父母的健康
  • 批准号:
    10660046
  • 财政年份:
    2023
  • 资助金额:
    $ 76.3万
  • 项目类别:
Understanding Longer-Living Older Adult Research: The Summer Program on Aging
了解长寿老年人研究:老龄化夏季项目
  • 批准号:
    476343
  • 财政年份:
    2022
  • 资助金额:
    $ 76.3万
  • 项目类别:
Role of sensory experience in the regulation of plasticity in the developing, adult and aging brain
感官体验在发育、成人和衰老大脑可塑性调节中的作用
  • 批准号:
    RGPIN-2019-04761
  • 财政年份:
    2022
  • 资助金额:
    $ 76.3万
  • 项目类别:
    Discovery Grants Program - Individual
Adult Cognitive and Neurobiological Indicators of Aging: Impact of Adversity and Social Support
成人衰老的认知和神经生物学指标:逆境和社会支持的影响
  • 批准号:
    10365348
  • 财政年份:
    2022
  • 资助金额:
    $ 76.3万
  • 项目类别:
Adult Cognitive and Neurobiological Indicators of Aging: Impact of Adversity and Social Support
成人衰老的认知和神经生物学指标:逆境和社会支持的影响
  • 批准号:
    10700796
  • 财政年份:
    2022
  • 资助金额:
    $ 76.3万
  • 项目类别:
Endogenous barcoding to determine complex dynamics of adult neurogenesis in aging and Alzheimer's disease
内源条形码确定衰老和阿尔茨海默病中成人神经发生的复杂动态
  • 批准号:
    10651861
  • 财政年份:
    2022
  • 资助金额:
    $ 76.3万
  • 项目类别:
Investigating the interface of epigenetics and metabolism underlying memory formation in the adult, aging, and AD brain
研究成人、衰老和 AD 大脑中记忆形成的表观遗传学和代谢界面
  • 批准号:
    10420533
  • 财政年份:
    2022
  • 资助金额:
    $ 76.3万
  • 项目类别:
Endogenous barcoding to determine complex dynamics of adult neurogenesis in aging and Alzheimer's disease
内源条形码确定衰老和阿尔茨海默病中成人神经发生的复杂动态
  • 批准号:
    10846200
  • 财政年份:
    2022
  • 资助金额:
    $ 76.3万
  • 项目类别:
THE DEVELOPMENT OF MECHANISM-BASED ADULT STEM CELL TREATMENTS TO COMBAT AGING PATHOLOGIES
开发基于机制的成人干细胞疗法来对抗衰老病理学
  • 批准号:
    10721544
  • 财政年份:
    2022
  • 资助金额:
    $ 76.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了